The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
Open accessAbstract
BACKGROUND: Diffuse low-grade and intermediate-grade gliomas (which together make up the lower-grade gliomas, World Health Organization grades II and III) have highly variable clinical behavior that is not adequately predicted on the basis of histologic class. Some are indolent; others quickly progress to glioblastoma. The uncertainty is compounded by interobserver variability in histologic diagnosis. Mutations in IDH, TP53, and ATRX and codeletion of chromosome arms 1p and 19q (1p/19q codeletion) have been implicated as clinically relevant markers of lower-grade gliomas. METHODS: We performed genomewide analyses of 293 lower-grade gliomas from adults, incorporating exome sequence, DNA copy number, DNA methylation, messenger RNA expression, microRNA expression, and targeted protein expression. These data were integrated and tested for correlation with clinical outcomes. RESULTS: Unsupervised clustering of mutations and data from RNA, DNA-copy-number, and DNA-methylation platforms uncovered concordant classification of three robust, nonoverlapping, prognostically significant subtypes of lower-grade glioma that were captured more accurately by IDH, 1p/19q, and TP53 status than by histologic class. Patients who had lower-grade gliomas with an IDH mutation and 1p/19q codeletion had the most favorable clinical outcomes. Their gliomas harbored mutations in CIC, FUBP1, NOTCH1, and the TERT promoter. Nearly all lower-grade gliomas with IDH mutations and no 1p/19q codeletion had mutations in TP53 (94%) and ATRX inactivation (86%). The large majority of lower-grade gliomas without an IDH mutation had genomic aberrations and clinical behavior strikingly similar to those found in primary glioblastoma. CONCLUSIONS: The integration of genomewide data from multiple platforms delineated three molecular classes of lower-grade gliomas that were more concordant with IDH, 1p/19q, and TP53 status than with histologic class. Lower-grade gliomas with an IDH mutation either had 1p/19q codeletion or carried a TP53 mutation. Most lower-grade gliomas without an IDH mutation were molecularly and clinically similar to glioblastoma. (Funded by the National Institutes of Health.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Gain-of-function IDH mutations are initiating events that define major clinical and prognostic classes of gliomas1,2.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Our patient’s tumor harbored mutations in TERT, FUBP1, and CIC, which are common alterations in oligodendroglioma, but not clinically relevant [46,47].”
From BPC 157 Therapy of Myotendinous Junction Injury in Rats (2025) · cites this paper as [47]
Experimental — accuracy not yet measuredIn the citing paper
“IDH WT astrocytomas are, for the most part, highly aggressive, having a median survival of 18 mo”
From Predicting cancer outcomes from histology and genomics using convolutional networks (2018) · cites this paper as [37]
In the citing paper
“Second, predicted risks are consistent with the published expected overall survivals associated with molecular subtypes (37).”
From Predicting cancer outcomes from histology and genomics using convolutional networks (2018) · cites this paper as [37]
In the citing paper
“and these have the lowest overall predicted risks consistent with overall survivals of 10+ y (37, 39).”
From Predicting cancer outcomes from histology and genomics using convolutional networks (2018) · cites this paper as [37]
In the citing paper
“IDH mutant astrocytomas are another subtype with considerably better overall survival ranging from 3 to 8 y”
From Predicting cancer outcomes from histology and genomics using convolutional networks (2018) · cites this paper as [37]
In the citing paper
“In recent years, two landmark genomic studies carried out in human glioma and acute myeloid leukaemia (AML) found mutations in IDH1/2 and it is now appreciated that these enzymes (which drive elevated production of D-2-HG) are the most frequently mutated metabolic genes in human cancer112-114.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [114]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,656
Ostrom, Q. T., Gittleman, H. R., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz‐Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 12,063
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
The Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia
Weng, A. P., Ferrando, A. A., Lee, W., Morris, J. P., Silverman, L. B., Sanchez-Irizarry, C., Blacklow, S. C., Look, A. T., & Aster, J. C. (2004) · Science · doi:10.1126/science.1102160 · Cited by 2,706
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
Glioma Groups Based on 1p/19q, IDH , and TERT Promoter Mutations in Tumors
Eckel‐Passow, J. E., Lachance, D. H., Molinaro, A. M., Walsh, K. M., Decker, P. A., Sicotte, H., Pekmezci, M., Rice, T., Kosel, M., Smirnov, I. V., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1407279 · Cited by 1,981
Flagged first, then by citations
1 of the 54 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Parker BC, 2013, J Clin Invest, 123, 855
Cited by
Sorted by citations
Items 401–500 of 1,002
Yahyanejad, S., King, H., Iglesias, V. S., Granton, P. V., Barbeau, L. M. O., van Hoof, S. J., Groot, A. J., Habets, R., Prickaerts, J., Chalmers, A. J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9275 · Cited by 82
Amide proton transfer imaging might predict survival and IDH mutation status in high-grade glioma
Joo, B., Han, K., Ahn, S. S., Choi, Y. S., Chang, J. H., Kang, S., Kim, S. H., Zhou, J., & Lee, S. (2019) · European Radiology · doi:10.1007/s00330-019-06203-x · Cited by 80
Machine learning and radiomic phenotyping of lower grade gliomas: improving survival prediction
Choi, Y. S., Ahn, S. S., Chang, J. H., Kang, S., Kim, E. H., Kim, S. H., Jain, R., & Lee, S. (2020) · European Radiology · doi:10.1007/s00330-020-06737-5 · Cited by 79
Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase–mutant Glioma
Spino, M., Kurz, S. C., Chiriboga, L. A., Serrano, J., Zeck, B., Sen, N., Patel, S. V., Shen, G., Vasudevaraja, V., Tsirigos, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2312 · Cited by 80
Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors
Schäfer, N., Gielen, G. H., Rauschenbach, L., Kebir, S., Till, A., Reinartz, R., Simon, M., Niehusmann, P., Kleinschnitz, C., Herrlinger, U., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1846-y · Cited by 83
Histone deacetylase inhibitors exert anti-tumor effects on human adherent and stem-like glioma cells
Was, H., Krol, S. K., Rotili, D., Mai, A., Wojtas, B., Kaminska, B., & Maleszewska, M. (2019) · Clinical Epigenetics · doi:10.1186/s13148-018-0598-5 · Cited by 78
The cIMPACT-NOW updates and their significance to current neuro-oncology practice
Castro, L. N. G., & Wesseling, P. (2020) · Neuro-Oncology Practice · doi:10.1093/nop/npaa055 · Cited by 78
Distinct metabolic hallmarks of WHO classified adult glioma subtypes
Björkblom, B., Wibom, C., Eriksson, M., Bergenheim, A. T., Sjöberg, R. L., Jonsson, P., Brännström, T., Antti, H., Sandström, M., & Melin, B. S. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac042 · Cited by 78
Szylberg, M., Sokal, P., Śledzińska, P., Bebyn, M. G., Krajewski, S., Szylberg, Ł., Szylberg, A., Szylberg, T., Krystkiewicz, K., Birski, M., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10082030 · Cited by 78
Reconstructing the molecular life history of gliomas
Barthel, F. P., Wesseling, P., & Verhaak, R. G. W. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1842-y · Cited by 86
A recurrent kinase domain mutation in PRKCA defines chordoid glioma of the third ventricle
Goode, B., Mondal, G., Hyun, M., Ruiz, D. G., Lin, Y.-H. T., Ziffle, J. V., Joseph, N. M., Onodera, C. S., Talevich, E., Grenert, J. P., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-02826-8 · Cited by 78
Clinical Management of Diffuse Low-Grade Gliomas
Lombardi, G., Barresi, V., Castellano, A., Tabouret, É., Pasqualetti, F., Salvalaggio, A., Cerretti, G., Caccese, M., Padovan, M., Zagonel, V., et al. (2020) · Cancers · doi:10.3390/cancers12103008 · Cited by 79
Chang, S. M., Zhang, J., Cairncross, J. G., Gilbert, M. R., Bahary, J.-P., Dolinskas, C. A., Chakravarti, A., Aldape, K., Bell, E. H., Schiff, D., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now236 · Cited by 78
Diffusion tensor image features predict IDH genotype in newly diagnosed WHO grade II/III gliomas
Eichinger, P., Alberts, E., Delbridge, C., Trebeschi, S., Valentinitsch, A., Bette, S. J., Huber, T. S., Gempt, J., Meyer, B., Schlegel, J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-13679-4 · Cited by 76
Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells
Reitman, Z. J., Paolella, B. R., Bergthold, G., Pelton, K., Becker, S., Jones, R. E., Sinai, C. E., Malkin, H., Huang, Y., Grimmett, L., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11493-2 · Cited by 78
Tumor diversity and the trade-off between universal cancer tasks
Hausser, J., Székely, P., Bar, N., Zimmer, A., Sheftel, H., Caldas, C., & Alon, U. (2019) · Nature Communications · doi:10.1038/s41467-019-13195-1 · Cited by 78
Fukuma, R., Yanagisawa, T., Kinoshita, M., Shinozaki, T., Arita, H., Kawaguchi, A., Takahashi, M., Narita, Y., Terakawa, Y., Tsuyuguchi, N., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-56767-3 · Cited by 76
Wong, B. S., Shah, S. R., Yankaskas, C. L., Bajpai, V. K., Wu, P.-H., Chin, D., Ifemembi, B., ReFaey, K., Schiapparelli, P. V., Zheng, X., et al. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-00621-9 · Cited by 76
Noureen, N., Wu, S., Lv, Y., Yang, J., Yung, W. K. A., Gelfond, J., Wang, X., Koul, D., Ludlow, A. T., & Zheng, S. (2021) · Nature Communications · doi:10.1038/s41467-020-20474-9 · Cited by 78
Context Matters: NOTCH Signatures and Pathway in Cancer Progression and Metastasis
Misiorek, J. O., Przybyszewska-Podstawka, A., Kałafut, J., Paziewska, B., Rolle, K., Rivero‐Müller, A., & Nees, M. (2021) · Cells · doi:10.3390/cells10010094 · Cited by 77
Comba, A., Faisal, S. M., Varela, M. L., Hollon, T. C., Al‐Holou, W. N., Umemura, Y., Núñez, F. J., Motsch, S., Castro, M. G., & Lowenstein, P. R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.703764 · Cited by 79
Ogino, H., Taylor, J. W., Nejo, T., Gibson, D., Watchmaker, P. B., Okada, K., Saijo, A., Tedesco, M. R., Shai, A., Wong, C. M., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci151239 · Cited by 76
Choudhury, A., Chen, W., Lucas, C. G., Bayley, J. C., Harmancı, A. S., Maas, S. L. N., Santagata, S., Klisch, T. J., Perry, A., Bi, W. L., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac224 · Cited by 76
Bongaarts, A., Giannikou, K., Reinten, R. J. A., Anink, J. J., Mills, J. D., Jansen, F. E., Spliet, W. G. M., den Dunnen, W. F. A., Coras, R., Blümcke, I., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20764 · Cited by 77
Han, Y., Xie, Z., Zang, Y., Zhang, S., Gu, D., Zhou, M., Gevaert, O., Wei, J., Li, C., Chen, H., et al. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2953-y · Cited by 76
Current State and Future Prospects of Immunotherapy for Glioma
Kamran, N., Alghamri, M. S., Núñez, F. J., Shah, D., Asad, A. S., Candolfi, M., Altshuler, D. B., Lowenstein, P. R., & Castro, M. G. (2018) · Immunotherapy · doi:10.2217/imt-2017-0122 · Cited by 77
Blümcke, I., Coras, R., Wefers, A. K., Capper, D., Aronica, E., Becker, A. J., Honavar, M., Stone, T. J., Jacques, T. S., Miyata, H., et al. (2018) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12522 · Cited by 75
An update on the central nervous system manifestations of Li–Fraumeni syndrome
Orr, B. A., Clay, M. R., Pinto, E. M., & Kesserwan, C. A. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02055-3 · Cited by 80
TCGA-TCIA Impact on Radiogenomics Cancer Research: A Systematic Review
Zanfardino, M., Pane, K., Mirabelli, P., Salvatore, M., & Franzese, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20236033 · Cited by 77
Glioma Grading and Determination of IDH Mutation Status and ATRX loss by DCE and ASL Perfusion
Brendle, C., Hempel, J.-M., Schittenhelm, J., Skardelly, M., Tabatabai, G., Bender, B., Ernemann, U., & Klose, U. (2017) · Clinical Neuroradiology · doi:10.1007/s00062-017-0590-z · Cited by 75
de Gooijer, M. C., Zhang, P., Weijer, R., Buil, L. C. M., Beijnen, J. H., & van Tellingen, O. (2017) · International Journal of Cancer · doi:10.1002/ijc.31052 · Cited by 75
Sex is an important prognostic factor for glioblastoma but not for nonglioblastoma
Gittleman, H. R., Ostrom, Q. T., Stetson, L. C., Waite, K. A., Hodges, T. R., Wright, C. H., Wright, J. M., III, Rubin, J. B., Berens, M. E., Lathia, J. D., et al. (2019) · Neuro-Oncology Practice · doi:10.1093/nop/npz019 · Cited by 75
Therapeutic Targets in Glioblastoma: Molecular Pathways, Emerging Strategies, and Future Directions
Tang, J., Karbhari, N., & Campian, J. L. (2025) · Cells · doi:10.3390/cells14070494 · Cited by 84
Molecular Testing of Brain Tumor
Park, S., Won, J., Kim, S., Lee, Y., Park, C., Kim, S., & Choi, S.-H. (2017) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2017.03.08 · Cited by 77
Zhang, L., He, L., Lugano, R., Roodakker, K. R., Bergqvist, M., Smits, A., & Dimberg, A. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy088 · Cited by 74
Inhibition of a K9/K36 demethylase by an H3.3 point mutation found in paediatric glioblastoma
Voon, H. P. J., Udugama, M., Lin, W., Hii, L. L., Law, R. H. P., Steer, D. L., Das, P. P., Mann, J. R., & Wong, L. H. (2018) · Nature Communications · doi:10.1038/s41467-018-05607-5 · Cited by 79
Li, Y., He, Z., Zhang, X.-N., Liu, Q., Chen, C., Zhu, Z., Chen, Q., Shi, Y., Yao, X.-H., Cui, Y., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.11.033 · Cited by 73
Turcan, Ş., & Cahill, D. P. (2018) · Seminars in Neurology · doi:10.1055/s-0037-1620238 · Cited by 73
Modeling epigenetic lesions that cause gliomas
Rahme, G. J., Javed, N. M., Puorro, K. L., Xin, S., Hovestadt, V., Johnstone, S. E., & Bernstein, B. (2023) · Cell · doi:10.1016/j.cell.2023.06.022 · Cited by 75
Gao, K., Li, G., Qu, Y., Wang, M., Cui, B., Ji, M., Shi, B., & Hou, P. (2015) · Oncotarget · doi:10.18632/oncotarget.6007 · Cited by 76
Sexual dimorphism in glioma glycolysis underlies sex differences in survival
Ippolito, J. E., Yim, A. K., Luo, J. R., Chinnaiyan, P., & Rubin, J. B. (2017) · JCI Insight · doi:10.1172/jci.insight.92142 · Cited by 76
Thust, S. C., Hassanein, S. M. A., Bisdas, S., Rees, J. H., Hyare, H., Maynard, J. A., Brandner, S., Tur, C., Jäger, H. R., Yousry, T. A., et al. (2018) · European Radiology · doi:10.1007/s00330-018-5351-0 · Cited by 73
Malzkorn, B., & Reifenberger, G. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000327 · Cited by 75
Wood, M. D., Halfpenny, A. M., & Moore, S. R. (2019) · Diagnostic Pathology · doi:10.1186/s13000-019-0802-8 · Cited by 74
Pediatric gliomas as neurodevelopmental disorders
Baker, S. J., Ellison, D. W., & Gutmann, D. H. (2015) · Glia · doi:10.1002/glia.22945 · Cited by 76
Kamimura, K., Nakajo, M., Yoneyama, T., Takumi, K., Kumagae, Y., Fukukura, Y., & Yoshiura, T. (2018) · Japanese Journal of Radiology · doi:10.1007/s11604-018-0787-3 · Cited by 71
Batchala, P. P., Muttikkal, T. J. E., Donahue, J., Patrie, J. T., Schiff, D., Fadul, C. E., Mrachek, K., Lopes, M. B. S., Jain, R., & Patel, S. H. (2019) · American Journal of Neuroradiology · doi:10.3174/ajnr.a5957 · Cited by 71
Identification of PIEZO1 as a potential prognostic marker in gliomas
Zhou, W., Liu, X., van Wijnbergen, J. W., Yuan, L., Liu, Y., Zhang, C., & Jia, W. (2020) · Scientific Reports · doi:10.1038/s41598-020-72886-8 · Cited by 74
Oncogenic and Tumor-Suppressive Functions of NOTCH Signaling in Glioma
Parmigiani, E., Taylor, V., & Giachino, C. (2020) · Cells · doi:10.3390/cells9102304 · Cited by 74
Adversarial deconfounding autoencoder for learning robust gene expression embeddings
Dincer, A. B., Janizek, J. D., & Lee, S. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa796 · Cited by 71
Pacia, C. P., Yuan, J., Yue, Y., Xu, L., Nazeri, A., Desai, R. R., Gach, H. M., Wang, X., Talcott, M., Chaudhuri, A. A., et al. (2021) · Theranostics · doi:10.7150/thno.65597 · Cited by 71
Lam, L. H. T., Do, D. T., Diep, D. T. N., Nguyet, D. L. N., Truong, Q. D., Tri, T. T., Thanh, H. N., & Le, N. Q. K. (2022) · NMR in Biomedicine · doi:10.1002/nbm.4792 · Cited by 71
Imperial, R. J. L., Toor, O. M., Hussain, A., Subramanian, J., & Masood, A. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.016 · Cited by 74
Lee, M. K., Park, J. E., Jo, Y., Park, S. Y., Kim, S. J., & Kim, H. S. (2019) · European Radiology · doi:10.1007/s00330-019-06395-2 · Cited by 71
Label-free brain tumor imaging using Raman-based methods
Hollon, T. C., & Orringer, D. A. (2021) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03380-z · Cited by 72
Fyllingen, E. H., Bø, L. E., Reinertsen, I., Jakola, A. S., Sagberg, L. M., Berntsen, E. M., Salvesen, Ø. O., & Solheim, O. S. (2021) · Acta Neurochirurgica · doi:10.1007/s00701-021-04802-6 · Cited by 70
Adult type diffuse gliomas in the new 2021 WHO Classification
Antonelli, M., & Poliani, P. L. (2022) · Pathologica · doi:10.32074/1591-951x-823 · Cited by 72
Detection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomas
Cai, J., Zhu, P., Zhang, C., Li, Q., Wang, Z., Li, G., Wang, G., Yang, P., Li, J., Han, B. R., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7650 · Cited by 72
Takano, S., Ishikawa, E., Sakamoto, N., Matsuda, M., Akutsu, H., Noguchi, M., Kato, Y., Yamamoto, T., & Matsumura, A. (2016) · Brain Tumor Pathology · doi:10.1007/s10014-016-0260-x · Cited by 70
Brindle, K. M., Izquierdo-García, J. L., Lewis, D. Y., Mair, R. J., & Wright, A. J. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.7636 · Cited by 70
Dissecting human gliomas by single-cell RNA sequencing
Tirosh, I., & Suvà, M. L. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox126 · Cited by 72
The association between copy number aberration, DNA methylation and gene expression in tumor samples
Sun, W., Bunn, P., Jin, C., Little, P., Zhabotynsky, V., Perou, C. M., Hayes, D. N., Chen, M., & Lin, D.-Y. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky131 · Cited by 70
Röver, L. K., Gevensleben, H., Dietrich, J., Bootz, F., Landsberg, J., Goltz, D., & Dietrich, D. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.01.016 · Cited by 73
Horbinski, C., Ligon, K. L., Brastianos, P. K., Huse, J. T., Venere, M., Chang, S. M., Buckner, J. C., Cloughesy, T. F., Jenkins, R. B., Giannini, C., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz119 · Cited by 70
Shankar, G. M., Lelic, N., Gill, C. M., Thorner, A. R., Hummelen, P. V., Wisoff, J. H., Loeffler, J. S., Brastianos, P. K., Shin, J. H., Borges, L. F., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1492-2 · Cited by 74
Zeng, W., Yang, Y., Liu, Z.-Z., Wen, Z., Chen, Y., Hu, X., Cheng, Q., Xiao, J., Zhao, J., & Chen, X. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000489954 · Cited by 69
Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas
Brat, D. J., Aldape, K., Bridge, J. A., Canoll, P., Colman, H., Hameed, M. R., Harris, B. T., Hattab, E. M., Huse, J. T., Jenkins, R. B., et al. (2022) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2021-0295-cp · Cited by 69
Precision medicine from the renal cancer genome
Riazalhosseini, Y., & Lathrop, M. G. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.133 · Cited by 69
Park, Y. W., Han, K., Ahn, S. S., Choi, Y. S., Chang, J. H., Kim, S. H., Kang, S., Kim, E. H., & Lee, S. (2018) · American Journal of Neuroradiology · doi:10.3174/ajnr.a5569 · Cited by 69
Grimm, S. A., & Chamberlain, M. C. (2016) · CNS Oncology · doi:10.2217/cns-2016-0002 · Cited by 69
Fatal correlation between YAP1 expression and glioma aggressiveness: clinical and molecular evidence
Guichet, P., Masliantsev, K., Tachon, G., Petropoulos, C., Godet, J., Ciron, D. L., Milin, S., Wager, M., & Karayan, L. (2018) · The Journal of Pathology · doi:10.1002/path.5133 · Cited by 68
The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study
Ramos‐Fresnedo, A., Pullen, M. W., Perez‐Vega, C., Domingo, R. A., Akinduro, O. O., Almeida, J. P., Suárez-Meade, P., Marenco-Hillembrand, L., Jentoft, M. E., Bendok, B. R., et al. (2022) · Journal of Neuro-Oncology · doi:10.1007/s11060-022-03960-6 · Cited by 68
Kalinina, J., Ahn, J. Y., Devi, N. S., Wang, L., Li, Y., Olson, J. J., Glantz, M., Smith, T. W., Kim, E. L., Giese, A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2965 · Cited by 72
Volumetric Analysis of Extent of Resection, Survival, and Surgical Outcomes for Insular Gliomas
Eseonu, C. I., ReFaey, K., García, Ó., Raghuraman, G., & Quiñones‐Hinojosa, A. (2017) · World Neurosurgery · doi:10.1016/j.wneu.2017.04.002 · Cited by 68
Khurshed, M., Molenaar, R. J., Lenting, K., Leenders, W. P. J., & Noorden, C. J. F. V. (2017) · Oncotarget · doi:10.18632/oncotarget.17106 · Cited by 72
Rodríguez, F. J., Brosnan‐Cashman, J. A., Allen, S. J., Vizcaíno, M. A., Giannini, C., Camelo-Piragua, S. I., Webb, M., Matsushita, M., Wadhwani, N. R., Tabbarah, A. Z., et al. (2018) · Brain Pathology · doi:10.1111/bpa.12646 · Cited by 69
Derks, J., Kulik, S. D., Wesseling, P., Numan, T., Hillebrand, A., van Dellen, E., Hamer, P. C. D. W., Geurts, J. J. G., Reijneveld, J. C., Stam, C. J., et al. (2019) · Brain and Behavior · doi:10.1002/brb3.1204 · Cited by 68
Nejo, T., Matsushita, H., Karasaki, T., Nomura, M., Saito, K., Tanaka, S., Takayanagi, S., Hana, T., Takahashi, S., Kitagawa, Y., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0599 · Cited by 69
Machine learning for cryosection pathology predicts the 2021 WHO classification of glioma
Nasrallah, M. P., Zhao, J., Tsai, C. C., Meredith, D., Marostica, E., Ligon, K. L., Golden, J. A., & Yu, K.-H. (2023) · Med · doi:10.1016/j.medj.2023.06.002 · Cited by 67
Christians, A., Adel-Horowski, A., Banan, R., Lehmann, U., Bartels, S., Behling, F., Barrantes‐Freer, A., Stadelmann, C., Rohde, V., Stockhammer, F., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0817-0 · Cited by 67
Koçak, B., Durmaz, E. Ş., Ates, E., Sel, İ., Güneş, S. T., Kaya, O. K., Zeynalova, A., & Kılıçkesmez, Ö. (2019) · European Radiology · doi:10.1007/s00330-019-06492-2 · Cited by 67
Adult Glioma WHO Classification Update, Genomics, and Imaging
Bai, J., Varghese, J., & Jain, R. (2020) · Topics in Magnetic Resonance Imaging · doi:10.1097/rmr.0000000000000234 · Cited by 68
Clinicopathological analysis of T2-FLAIR mismatch sign in lower-grade gliomas
Deguchi, S., Oishi, T., Mitsuya, K., Kakuda, Y., Endo, M., Sugino, T., & Hayashi, N. (2020) · Scientific Reports · doi:10.1038/s41598-020-67244-7 · Cited by 67
Park, S. I., Suh, C. H., Guenette, J. P., Huang, R. Y., & Kim, H. S. (2021) · European Radiology · doi:10.1007/s00330-020-07467-4 · Cited by 67
Introduction to radiomics and radiogenomics in neuro-oncology: implications and challenges
Beig, N. G., Bera, K., & Tiwari, P. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa148 · Cited by 67
Metabolomics profiling in plasma samples from glioma patients correlates with tumor phenotypes
Zhao, H., Heimberger, A. B., Lu, Z., Wu, X., Hodges, T. R., Song, R., & Shen, J. (2016) · Oncotarget · doi:10.18632/oncotarget.7974 · Cited by 67
Chaumeil, M. M., Radoul, M., Najac, C., Eriksson, P., Viswanath, P., Blough, M. D., Chesnelong, C., Luchman, H. A., Cairncross, J. G., & Ronen, S. M. (2016) · NeuroImage Clinical · doi:10.1016/j.nicl.2016.06.018 · Cited by 67
Su, C., Liu, C., Zhao, L., Jiang, J., Zhang, J., Li, S., Zhu, W., & Wang, J. (2017) · American Journal of Neuroradiology · doi:10.3174/ajnr.a5301 · Cited by 67
Labrèche, K., Kinnersley, B., Berzero, G., Stefano, A. L. D., Rahimian, A., Detrait, I., Marie, Y., Grenier‐Boley, B., Hoang‐Xuan, K., Delattre, J., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1825-z · Cited by 70
Wu, C., Jain, R., Radmanesh, A., Poisson, L., Guo, W., Zagzag, D., Snuderl, M., Placantonakis, D. G., Golfinos, J. G., & Chi, A. S. (2018) · American Journal of Neuroradiology · doi:10.3174/ajnr.a5794 · Cited by 67
Interactive phenotyping of large-scale histology imaging data with HistomicsML
Nalisnik, M., Amgad, M. T., Lee, S., Halani, S. H., Vega, J. E. V., Brat, D. J., Gutman, D. A., & Cooper, L. (2017) · Scientific Reports · doi:10.1038/s41598-017-15092-3 · Cited by 67
Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities
Reinhardt, A., Stichel, D., Schrimpf, D., Koelsche, C., Wefers, A. K., Ebrahimi, A., Sievers, P., Huang, K. T. L., Casalini, M. B., Fernández‐Klett, F., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0801-8 · Cited by 67
Allosteric Antagonist Modulation of TRPV2 by Piperlongumine Impairs Glioblastoma Progression
Conde, J., Pumroy, R. A., Baker, C., Rodrigues, T., Guerreiro, A., Sousa, B. B., Marques, M. C., de Almeida, B. P., Lee, S., Leites, E. P., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00070 · Cited by 66
Radiogenomics for Precision Medicine With a Big Data Analytics Perspective
Panayides, A. S., Pattichis, M. S., Leandrou, S., Pitris, C., Constantinidou, A., & Pattichis, C. S. (2019) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2018.2879381 · Cited by 66
Binder, H., Willscher, E., Loeffler‐Wirth, H., Hopp, L., Jones, D., Pfister, S. M., Kreuz, M., Gramatzki, D., Fortenbacher, E., Hentschel, B., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0704-8 · Cited by 65
Diseases of the Brain, Head and Neck, Spine 2020–2023
Hodler, J., Huch, R., & von Schulthess, G. K. (2020) · IDKD Springer series · doi:10.1007/978-3-030-38490-6 · Cited by 65
Multiparametric MRI-based differentiation of WHO grade II/III glioma and WHO grade IV glioblastoma
Wiestler, B., Kluge, A., Lukas, M., Gempt, J., Ringel, F. A., Schlegel, J., Meyer, B., Zimmer, C., Förster, S., Pyka, T., et al. (2016) · Scientific Reports · doi:10.1038/srep35142 · Cited by 65
Leather, T., Jenkinson, M. D., Das, K., & Poptani, H. (2017) · Metabolites · doi:10.3390/metabo7020029 · Cited by 65
Beyond IDH-Mutation: Emerging Molecular Diagnostic and Prognostic Features in Adult Diffuse Gliomas
Mirchia, K., & Richardson, T. E. (2020) · Cancers · doi:10.3390/cancers12071817 · Cited by 64
Prediction of Glioma Grades Using Deep Learning with Wavelet Radiomic Features
Çınarer, G., Emiroğlu, B. G., & Yurttakal, A. H. (2020) · Applied Sciences · doi:10.3390/app10186296 · Cited by 64
Metadata
- Authors
- The Cancer Genome Atlas Research Network
- Affiliations
- Emory University (US)
- Corresponding author
- The Cancer Genome Atlas Research Network
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-06-25
- Volume
- 372
- Issue
- 26
- Pages
- 2481-2498
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4530011
- OpenAlex
- W1812256879
- Cited by
- 3,148
- References
- 54
- Citations by year
- 2026: 139 · 2025: 196 · 2024: 248 · 2023: 282 · 2022: 371 · 2021: 341 · 2020: 366 · 2019: 314 · 2018: 311 · 2017: 284 · 2016: 226 · 2015: 60
- FWCI
- 164.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- CaltechAUTHORS (California Institute of Technology) (submittedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, other-oa)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- National Institutes of Health
- National Human Genome Research Institute (U54HG003067, U54HG003079, U54HG003273, U54HG007990)
- National Cancer Institute (U24CA194362, U24CA126554, U24CA143882, U24CA143843, U24CA143840, U24CA126546, U24CA143858, U24CA126543, U24CA144025, U24CA126563, U01CA168394, U24CA143866, U24CA143883, U24CA143845, U24CA126544, R01CA163722, U24CA180951, U24CA143867, U24CA143848, U24CA143799, U24CA126551, U24CA143835, U24CA126561, P30CA008748, P30CA016672, U24CA143731)
- National Institute of Neurological Disorders and Stroke (R01NS081125)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- glioma molecular subtypes, IDH mutation, 1p/19q codeletion, TP53 mutation, TERT promoter mutation, NOTCH1 mutation, CIC mutation, glioblastoma, prognostic factors, DNA methylation, DNA copy number, gene expression, microRNA expression
- MeSH terms
- Adolescent, Adult, Aged, Chromosomes, Human, Pair 1, Chromosomes, Human, Pair 19, DNA, Neoplasm, Female, Glioblastoma, Glioma, Humans, Male, Middle Aged, Mutation, Signal Transduction, Cluster Analysis, Proportional Hazards Models, Genes, p53, Sequence Analysis, DNA, Kaplan-Meier Estimate, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
